Labeling Policy Team
The Labeling Policy Team (LPT) [formerly known as the Labeling Development Team] is located in Office of New Drug Policy (ONDP) in the Office of New Drugs (OND) in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).
Our Mission
The LPT develops prescription drug labeling regulations, FDA guidance, and CDER policies, and oversees their implementation to help ensure that the Prescribing Information (PI):
- Is a useful communication tool for health care practitioners
- Meets statutory/regulatory requirements and is appropriately consistent with guidance recommendations and CDER policies
- Is appropriately consistent across CDER-regulated prescription drug and biological products
Responsibilities Include:*
- Assists in labeling review [through Associate Directors for Labeling (ADLs)]
- Serves as OND’s point of contact for labeling issues with policy implications
- Oversees labeling practices to improve labeling quality
- Provides labeling review training
- Mentors OND ADLs and leads ADL workshops
- Develops and maintains labeling review resources for CDER and stakeholders
- Leads labeling outreach to stakeholders
- Participates in and leads labeling policy initiatives
* Under this heading, labeling refers to the PI for human prescription drug and biological products
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Office of New Drugs, Office of New Drug Policy, Labeling Policy Team
10903 New Hampshire Avenue, Building 22
Silver Spring, MD 20993
Phone: 240-402-4768 (for general questions about the Prescribing Information)
For questions about FDA-approved patient labeling or carton/container labeling, please contact druginfo@fda.hhs.gov, 1-855-543-3784, or 1-301-796-3400.